Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer-Reference-Cited by-同舟云学术

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer

Published:2023-09-08 Issue:18 Volume:66 Page:13280-13303
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Xiang Weiguo¹,Zhao Lijie¹,Han Xin¹,Xu Tianfeng¹^ORCID,Kregel Steven²³,Wang Mi¹,Miao Bukeyan¹,Qin Chong¹^ORCID,Wang Mingliang¹,McEachern Donna¹,Lu Jianfeng¹,Bai Longchuan¹⁴,Yang Chao-Yie¹^ORCID,Kirchhoff Paul D.¹,Takyi-Williams John⁵,Wang Lu⁵,Wen Bo⁵,Sun Duxin⁴⁵^ORCID,Ator Mark⁶,Mckean Robert⁶,Chinnaiyan Arul M.²³⁴⁷,Wang Shaomeng¹³⁴⁸⁹^ORCID

Affiliation:

1. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States

3. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States

5. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States

6. Oncopia Therapeutics Inc, 2 West Liberty Blvd., Malvern, Pennsylvania 19355, United States

7. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan 48109, United States

8. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States

9. Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Proteovant Therapeutics Inc

Oncopia Therapeutics Inc

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01264

Reference48 articles.

1. Loss and revival of androgen receptor signaling in advanced prostate cancer

2. Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer

3. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors

4. Second generation androgen receptor antagonists and challenges in prostate cancer treatment

5. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9;Journal of Medicinal Chemistry;2024-08-12

3. Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer;Journal of Medicinal Chemistry;2024-07-11

4. Application and challenges of nitrogen heterocycles in PROTAC linker;European Journal of Medicinal Chemistry;2024-07

5. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer;Bioorganic Chemistry;2024-07